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p38 MAPK signalling regulates 
cytokine production in IL-33 
stimulated Type 2 Innate Lymphoid 
cells
Tsvetana petrova  1, Jelena pesic2, Katerina pardali2, Matthias Gaestel  3 & 
J. Simon C. Arthur1*
Type 2 Innate lymphoid cells (ILC2s) are implicated in helminth infections and asthma where they play a 
role in the production of Th2-type cytokines. ILC2s express the IL-33 receptor and are a major cell type 
thought to mediate the effects of this cytokine in vivo. To study the signalling pathways that mediate 
IL-33 induced cytokine production, a culture system was set up to obtain pure populations of ILC2s 
from mice. Inhibitors of the p38α/β and ERK1/2 MAPK pathways reduced the production of IL-5, IL-6, 
IL-9, IL-13 and GM-CSF by ILC2 in response to IL-33, with inhibition of p38 having the greatest effect. 
MK2 and 3 are kinases activated by p38α; MK2/3 inhibitors or knockout of MK2/3 in mice reduced 
the production of IL-6 and IL-13 (two cytokines implicated in asthma) but not IL-5, IL-9 or GM-CSF in 
response to IL-33. MK2/3 inhibition also suppressed IL-6 and IL-13 production by human ILC2s. MK2/3 
were required for maximal S6 phosphorylation, suggesting an input from the p38α-MK2/3 pathway to 
mTOR1 activation in ILC2s. The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, 
which would be consistent with a model in which MK2/3 regulate IL-6 and IL-13 via mTORC1 activation 
in ILC2s.
Innate lymphoid cells (ILCs) are a recently identified group of lymphocytes acting within the innate immune sys-
tem. ILCs lack antigen specific receptors, however in terms of the cytokines they produce they mimic various Th 
cell subsets. ILCs are found in both lymphoid and non-lymphoid tissues, particularly at the barrier sites includ-
ing skin, respiratory and gastrointestinal systems1–4. Based on their effector function, cell surface markers and 
the transcription factors required for their development, ILCs can be subdivided into several distinct groups1,2. 
Group 1 includes NK cells and ILC1 cells, which are involved in protective immunity to viral infections and 
antimicrobial responses. The second group comprises of type 2 innate lymphoid cells (ILC2). ILC2 cells secrete 
type two cytokines and are implicated in responses to helminth infection, asthma and atopic diseases. The third 
group includes the lymphoid tissue inducer cells and ILC3. In 2017, a potential new group of ILC with regulatory 
functions was discovered. ILCreg are found in human and mouse gut and limit the activity of ILC1 and ILC3 by 
secreting the anti-inflammatory cytokine IL-105.
The first evidence for the existence of ILC2 cells was found in 2006 when Fallon et al. showed that during 
infection with the helminth Nippostrongylus brasilienis a population of non-T and non-B cells secrete IL-4, IL-5 
and IL-13 and promote helminth expulsion6. In 2010, several labs reported the characterisation of ILC2s as a 
distinct population of cells, which were initially referred to as either neuocytes, innate helper 2 cells or natural 
helper cells7–9. ILC2s are found in the lymphoid tissues such as spleen and mesenteric lymph nodes, as well as in 
some non-lymphoid organs including fat associated lymphoid clusters, lungs, skin and liver. In mice, ILC2 are 
characterised by the lack of expression of surface markers of other immune cells (CD3, CD4, CD8, CD19, CD11b, 
CD11c, F4/80, FcεR,) and the expression of the IL-7R, IL-33 receptor (ST2), IL-25 receptor (IL-17RB), KLRG1, 
ICOS and c-kit10. Human ILC2s are lineage negative and express IL-7R, the prostaglandin receptor CRTH2 and 
CD16111. ILC2 responses can be triggered by the epithelial derived cytokines IL-33, IL-25 or TSLP. In addition, 
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lipid mediators such as prostaglandins and leukotrienes or neuronal derived neuropeptides can also induce ILC2 
activation12.
Murine ILC2s from various tissues including mesenteric fat, lungs, bone marrow and small intestine express 
the IL-33 receptor chain ST2, which is encoded by the Il1rl1 gene13. Human ILC2 isolated from the skin or 
white adipose tissues also express ST214. IL-33 is considered as one of the most prominent activators of the ILC2 
function15. IL-33 induces production of the type two cytokines both in human and murine ILC2 during in vitro 
stimulation14,16,17. Upon in vivo administration of IL-33 in mice, ILC2 are able to produce IL-5 and IL-1318. ILC2s 
are also the predominant source of IL-13 during early stage of N. brasiliensis infection and loss of IL-33 led to sub-
stantial reduction in the ILC2-derived IL-13 during N. brasiliensis without affecting the Th2 responses8,19. Because 
of their ability to mount a strong response to IL-33 stimulation, ILC2 have been proposed to be involved in the 
pathology of asthma20,21. In addition to stimulating cytokine production, IL-33 is also required for ILC2 egress 
from the bone marrow and as a result Il33−/− and Il1rl1−/− mice have an increase in ILC2 precursors in the bone 
marrow, but decreased numbers of mature ILC2s in the periphery22. This might be due to stimulation with IL-33 
leading to the downregulation of the chemokine receptor CXCR4 which regulates the retention of developing 
leukocytes in the bone marrow22,23.
IL-33 is pleiotropic cytokine that plays key role in regulating both innate and adaptive immunity. IL-33 was 
described in 2005 by Schmitz et al. as a novel member of the IL-1 superfamily and that was able to bind to 
the orphan IL-1 Receptor family member ST2 (the suppressor of tumorigenic 2)24. IL-33 was later shown to be 
identical to a protein called nuclear factor from high endothelial venules (NF-HEV), which had previously been 
identified in endothelial cells25. IL-33 is constitutively expressed in a number of cells outside the immune system, 
notably epithelial and endothelial cells, where it localises to the nucleus26–31. Unlike IL-1β, IL-33 does not possess 
a secretory sequence and is not processed by the inflammasome prior to its release. Instead IL-33 is released from 
cells undergoing necrosis and is proposed to act as an “alarmin”32,33. Once released IL-33 has been proposed to 
act on a number of cells in addition to ILC2s including Th2 cell, Tregs and mast cells24,34–37. IL-33 stimulates cells 
via a heterodimer receptor made up of the IL-33 specific ST2 chain and the IL-1RAcP38,39. Like other IL-1 family 
receptors, the IL-33 requires the adaptor protein MyD88 to activate downstream signalling40. MyD88 dependent 
signalling has been more extensively studied in the context of IL-1 and Toll like receptor responses41,42, however 
the major upstream components of the pathway appear to be similar for IL-33 signalling. Activation of the recep-
tor allows recruitment of MyD88, which in turn recruits IRAK4 and the IRAK1/2. Both IRAK1 and IRAK2 can 
interact with Traf6, resulting in the formation of hybrid K63/linear polyubiquitin chains and the activation of 
downstream signalling pathways including MAPK and NF-κB43–45. In line with this, knockout of Traf6 blocked 
the ability of IL-33 to activate NF-κB as well as the p38 and JNK MAPK pathways46. In mast cells, the p38 MAPK 
cascade has been found to be important for the production of a number of cytokines, including TNF, IL-6, IL-13 
and GM-CSF, in response to IL-33 stimulation47. p38α activates the downstream kinases MK2 and MK342 and in 
mast cells, MK2 and 3 are required for the p38α mediated regulation of TNF, IL-6, IL-13 and GM-CSF production 
by IL-3347,48.
The intracellular signalling controlling cytokines in ILC2s has not been extensively studied. One drawback 
to analysing signalling with ILC2s is their low number in vivo. We report here a method for culture of ILC2 cells 
from the mesenteric fat in mice. Using these cells, we show that p38 and to a lesser extent ERK1/2 are required 
for the IL-33 induced production of IL-5, IL-6, IL-9, IL-13 and GM-CSF in response to IL-33 treatment. Of these 
cytokines, IL-6 and IL-13 were regulated by the p38α activated kinases MK2 and 3, while IL-5, IL-9 and GM-CSF 
production were independent of MK2/3.
Results
ILC2s cultured from mesenteric fat respond to IL-33. In order to study the signalling pathways 
involved in regulating cytokine production, a culture system for ILC2s was set up. Initially ILC2 populations 
were analysed from the lung, white adipose tissue, mesenteric fat and lymph nodes. Single cell suspensions were 
prepared from these tissues and stained with CD45, a cocktail of lineage markers (CD3e, CD8, CD19, CD11b, 
CD11c, F4/80, Gr-1 and NK1.1), KLRG1, Sca-1 ST2 and c-kit and analysed by flow cytometry. ILC2 were defined 
as CD45+ve/Lin−ve/KLRG1+ve/Sca1+ve (Fig. 1A). As a percentage of starting cells, ILC2s were present at highest 
levels in the mesenteric fat compared to the other tissues examined. ILC2 from the different tissues were further 
characterised for c-kit and ST2 expression. Of the tissues analysed, the ILC2s in the mesentery and white adipose 
tissue expressed the highest levels of ST2 (Fig. 1A). Based on this, the mesenteric fat was chosen as a source of 
ILC2s for culture to study IL-33 induced signalling.
To culture ILC2s, two rounds of magnetic sorting was used to enrich ILC2s from the mesenteric fat. The first 
round used a cocktail of biotinylated antibodies against CD3ε, B220, CD19, Ly-6G/Ly-6C (Gr-1), CD11b, TER-
119, NK1.1 and F4/80 and streptavidin-conjugated magnetic beads to deplete other immune cells. To further 
enrich for ILC2 cells, a second round of magnetic selection was carried out to positively select the CD45+ve cells. 
Flow cytometry analysis of the depleted mesenteric cells, showed that most of the other immune cells were effec-
tively depleted and majority of the CD45+ve cells were lineage negative. A population of CD45−ve cells however 
remained following the magnetic selections (Fig. 1B). To increase the purity, the cells were then cultured in IL-7 
(10 ng/mL) and IL-2 (20 ng/mL) for 5 days. At the end of this culture,>99% of the live cells were CD45+ve and 
of these >97% were positive for the ILC2 markers Sca1 and KLRG1 (Fig. 1C). Typically a yield of 10000–20000 
cells per mouse was obtained using this protocol. GATA3 is required for ILC2 development and function49,50. 
GATA3 was expressed in cultured ILC2, although levels were increased compared to freshly isolated mesenteric 
ILC2s. ILC2s are also reported to express receptors ST2, CD127, CD25 and c-kit10,18, and so the levels of these 
proteins on the cell surface was examined by flow cytometry. Both freshly isolated mesenteric and cultured ILC2s 
expressed the IL-33 receptor ST2 (Supplementary Fig. 1). Cultured ILC2s also expressed the IL-7 receptor α chain 
CD127 and the IL-2 receptor α chain CD25, however cell surface levels of CD127 were lower and CD25 higher 
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Figure 1. Characterisation and purification of ILC2 cells. (A) Flow cytometry gating of ILC2 cells in 
mouse lungs, mesenteric fat, epididymal white adipose tissue (WAT) and mesenteric lymph nodes (mLN). 
Cells were stained as described in materials and methods and doublets and were excluded using FSC-A 
and FSC-W. Upper panels show percentages of Lineage−veCD45+ve of live DAPI−ve cells. The lineage 
negative immune cells were further analysed for expression of KLRG1 and Sca1 and ILC2 were defined as 
Lineage−veCD45+veKLRG1+veSca1+ve. Lower panels show expression of ST2 and c-kit in the ILC2 cells. (B,C) 
Representative flow cytometry plots showing the purity of ILC2 cells after depletion of Lineage positive cells 
(CD3ε, B220, CD19, Ly-6G/Ly-6C (Gr-1), CD11b, CD11c, TER-119, NK1.1 and F4/80) and positive selection of 
CD45 cells (B) and after magnetic sorting and culturing in IL-2 (20 ng/ml) and IL-7 (10 ng/ml) for 5 days (C).
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than in freshly isolated ILC2s (Supplementary Fig. 1). This may reflect the use of IL-2 and IL-7 in the culture. 
Cultured ILC2s also expressed higher levels of c-kit than freshly activated ILC2s (Supplementary Fig. 1). This 
may reflect an upregulation of c-kit by cytokines in the culture media; c-kit expression on human ILC2s has been 
found to be upregulated by a combination of TLSP and IL-25 or TLSP and IL-3351. The expression of c-kit on 
human c-kit high and c-kit low ILC2 populations has also been found to be affected by the cytokine makeup of 
the culture media52.
Cultured ILC2 response to IL-33. In mast cells, IL-33 has been shown to activate the p38α and ERK1/2 
MAPK cascades47, so the activation of these pathways was used to determine if the cultured ILC2s respond to 
IL-33. Cells were stimulated with IL-33 and the activation of ERK1/2 and p38 determined by flow cytometry 
using antibodies that recognize either ERK1/2 or p38α only when phosphorylated on their TXY activation motifs. 
This showed that IL-33 was able to induce the activation of both ERK1/2 and p38α in the cultured ILC2s (Fig. 2).
Previous reports have shown that ILC2s can produce several cytokines including IL-5, IL-6, IL-9, IL-13 and 
GM-CSF, and the amount of secreted cytokine present in the media increases over 3 to 5 days of stimulation. 
In agreement with this, ILC2s purified from the mesenteric fat by FACS, secreted IL-5, IL-6, IL-9, IL-13 and 
GM-CSF in response to IL-33 (Fig. 3A). While low levels of these cytokines could be detected in the culture 
supernatant by 24 h, their levels were increased at 3 and 5 days post stimulation. Similar to the FACS sorted ILC2s, 
the cultured ILC2 also produced IL-5, IL-6, IL-9, IL-13 and GM-CSF in response to IL-33, however the kinetics of 
cytokine production was in general faster than in the FACS sorted cells (Fig. 3B). ILC2s have also been reported 
to respond to IL-25 and TSLP (reviewed in53). Neither IL-25 or TSLP were sufficient to stimulate cytokine pro-
duction on their own in the cultured ILC2s, consistent with previous reports that these cytokines on their own 
are not effective at inducing cytokine production in isolated ILC2s7. TSLP however was able to potentiate IL-33 
induced production of IL-9 and IL-13 (Supplementary Fig. 2). It is possible that the presence IL-2 in the culture 
medium during the initial growth period having a priming effect on the ILC2s, as previous studies has shown 
that co-stimulation with IL-2 can increase cytokine production in response to IL-33 in ILC2s7,21,54. In line with 
this, co-stimulation with IL-33 and IL-2 did not further potentiate cytokine production in the cultured ILC2s 
(Fig. 3C). To further examine this, cultured ILC2s were rested in the absence of IL-2 for 16 h before stimulation 
with IL-33 or a combination of IL-33 and IL-2. In these experiments a combination of IL-2 and IL-33 did result in 
an increase in cytokine production relative to IL-33 alone (Fig. 3D).
In contrast to what has been observed in IL-33 stimulated mast cells, neither the ex vivo cells or the cultured 
ILC2s produced detectable levels of TNF in response to IL-33 stimulation (data not shown). In mast cells IL-33 
regulates cytokine production at least in part by regulating the level of cytokine mRNAs. To determine if this also 
occurred in ILC2s, total RNA was isolated from control or IL-33 stimulated ILC2s and analysed by qPCR. This 
showed that IL-33 increased the level of the mRNA for IL-5, IL-6, IL-9, IL-13 and GM-CSF (Fig. 4).
p38 MAPK signalling drives cytokine production in ILC2s. To examine the role of MAPK signal-
ling pathways in cytokine production in ILC2 cells, specific inhibitors of the ERK1/2 and p38 MAPK pathways 
were used. PD184352 inhibits MKK1/2 and therefore blocks the activation of ERK1/255 (Supplementary Fig. 3) 
while VX745 is an inhibitor of p38α and β56,57. Prolonged stimulation of cultured ILC2s with IL-33 for 3 to 5 
days results in an increase in ILC2 number, and this was reduced by the presence of either VX745 or PD184352 
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Figure 2. IL-33 induces activation of p38 and ERK1/2 in ILC2s. Cultured ILC2 cells were rested for 2 hours 
before stimulation with 100 ng/ml of IL-33 for the indicated time points. Cells were fixed, permeabilised and 
stained for p-ERK1/2 and p-p38. Representative histograms of p-p38 and p-ERK at 0 and 20 minutes are shown 
and plots show average of the median fluorescence intensity (MFI) and standard deviation (SD) of p-p38 and 
p-ERK1/2 from 3 independent stimulations of cultures ILC2 from one mouse. Results are representative of 
three experiments.
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Figure 3. IL-33 dependent cytokine production in ILC2 cells. (A) ILC2 cells (DAPI−veLineage−
veCD45+veKLRG1+veSca1+ve) cells were isolated from the mesenteric fat by FACS. Cells were plated at 5 × 103 
cells per well and stimulated ex vivo with IL-33 (100 ng/ml) or left unstimulated. Supernatants were collected 
1, 2 and 5 days after the stimulation and IL-5, IL-6, IL-9, IL-13 and GM-CSF by multiplex cytokine assay. Plots 
show mean concentrations ±SD for 4 stimulations. (B) ILC2 cells were cultured from the mesenteric fat as 
described in the methods. Cells were then plated at 5 × 103 cells per well with or without IL-33 (100 ng/ml). 
Culture media was sampled at 1, 2 and 5 days after the stimulation to measure cytokine production. Plots show 
mean of 4 biological replicates ±SD. (C) Cytokine production in cultured ILC2 cells stimulated for 24 hours 
with IL-33 (100 ng/ml) alone or IL-33 and IL-2 (20 ng/ml). The stimulation was done in triplicate and error bars 
show the mean values and standard deviation. nd indicates cytokine levels were below detectable limits in the 
assay. (D) Cultured ILC2 cells were rested for 16 h in media containing no IL-2 before stimulation with IL-33 
(100 ng/ml) and IL-2 (20 ng/ml) as indicated in the figure. The stimulation was done in triplicate and error bars 
show the mean values and standard deviation. Significance between samples was calculated using the one-way 
ANOVA test followed by the Tukey’s post hoc test.
6Scientific RepoRtS |         (2020) 10:3479  | https://doi.org/10.1038/s41598-020-60089-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
(Supplementary Fig. 4). Cell cycle analysis showed that IL-33 stimulated an increase in the proportion of cells in 
the S and G2/M phases of the cell cycle. The addition of VX745 or PD184352 before stimulation with IL-33 did 
not affect the percentages of cells in the different cell cycle stages. This may indicate the inhibitors affected ILC2 
survival rather than proliferation (Supplementary Fig. 5). Thus, at longer time points it is difficult to dissect an 
effect of the inhibitor on cell number from a direct effect of cytokine production. To avoid this complication, fur-
ther experiments to study cytokine production were carried out using 24 h stimulations with IL-33 and corrected 
for the number of live cells at the end of the stimulation. At this time point, the presence or absence of VX745 
or PD184352 did not greatly affect numbers of ILC2s in IL-33 stimulated cultures (Fig. 5A). The p38 inhibitor 
greatly reduced the induction of IL-5, IL-6, IL-9, IL-13 and GM-CSF (Fig. 5B–F). Blocking ERK1/2 activation 
with PD184352 also reduced IL-33 induced cytokine production. For IL-13, IL-9 and IL-5 the degree of inhibition 
approached that seen with the p38 inhibitor. For IL-6 and GM-CSF, inhibition with PD184352 was less effective 
than with VX745 (Fig. 5B–F).
MK2 and 2 regulate IL-6 and IL-13 production downstream of p38 in ILC2s. As blocking p38 had 
the biggest effect on cytokine production, this was investigated further. In IL-33 stimulated mast cells, MK2 and 
3 act downstream of p38 in the control of TNF, IL-6, IL-13 and GM-CSF production as well as the production of 
the chemokines CCL3 and CCL447. The role of MK2 and 3 in ILC2s was therefore examined using both MK2/3 
inhibitors and MK2/3 knockout mice.
The numbers of ILC2s in the lungs, mesenteric lymph nodes, mesenteric fat and epididymal white adipose 
tissue (eWAT) of MK2/3 double knockout mice were determined to check that the loss of MK2 and 3 did not 
affect ILC2 differentiation. Although there was an increase of the Lineage negative CD45+ve immune cells in the 
lungs, mesentery and eWAT in the knock out mice, the percentages of KLRG1+veSca1+ve ILC2 cells was lower. As 
a result, absolute numbers of ILC2s were not significantly different from those in the WT mice (p > 0.05, students 
test, Fig. 6A–E). Total numbers of ILC2 in the lymph nodes of the MK2/3 knockout mice were reduced relative to 
the numbers in wild type mice. Interestingly, the expression of KLRG1 was lower in the eWAT of MK2/3 knock 
out ILC2 (Supplementary Fig. 6). Although KLRG1 is an inhibitory ITIM motif containing receptor, the upregu-
lation of KLRG1 expression has been associated with the activation of ILC258. Hence, ILC2 in the eWAT of MK2/3 
knockout mice might have a less activated phenotype. The production of IL-5, IL-9 and GM-CSF in response to 
IL-33 stimulation was similar between wild type and MK2/3 knockout cells, indicating that these cytokines were 
regulated by p38 independently of MK2 and 3. The production of IL-6 and IL-13 was however decreased in the 
MK2/3 knockout ILC2s relative to wild type cells (Fig. 6F). As it is possible that this could be due to a develop-
mental role for MK2/3 rather than a direct effect of cytokine production, the effect of acutely inhibiting MK2 and 
3 was examined. Cmp2s is a highly selective inhibitor of MK2 and 3. It did not affect ILC2 cell numbers following 
24 h of IL-33 stimulation (Fig. 7A). Similar to the results in MK2/3 knockout cells (Fig. 7B) Cmp2s decreased the 
production of IL-6 and IL-13 in response to IL-33 stimulation in wild type cells. Cmp2s did not affect IL-5 or 
GM-CSF production. The above data indicated that a p38 – MK2/3 dependent pathway regulated IL-6 and IL-13 
production in murine ILC2s. To see if something similar occurred in human ILC2s, human ILC2 cells were iso-
lated from peripheral blood and stimulated ex vivo. As these cells had not been primed, they were stimulated with 
IL-33 in combination with IL-2, IL-25 and TSLP, a combination previously found to result in cytokine production 
in these cells59. While the absolute level of IL-6 and IL-13 produced varied across donors, pretreatment of the cells 
with either VX-745 or Cmp2s consistently reduced IL-6 and IL-13 production (Fig. 7C,D).
In CD4+ve T cells, loss of MK2 and has been shown to reduce activation of the mTORC1 pathway, as judged 
by phosphorylation of S6 downstream of TORC160, the potential for MK2/3 to regulate mTORC1 in ILC2 was 
examined. The treatment of ILC2s with IL-33 induced a rapid upregulation of S6 phosphorylation, which was 
completely reversed by treatment with the mTORC1 inhibitor rapamycin (Fig. 8A). Both the p38α/β inhibitor 
VX745 and the MK2 inhibitor Cmp2s blocked the IL-33 induced phosphorylation of S6 in ILC2s suggesting the 
p38α – MK2/3 pathway acts upstream of mTORC1 in ILC2s (Fig. 8A). To determine if this regulation might 
contribute to the ability of MK2/3 to regulate IL-6 and IL-13 production, ILC2 were stimulated with IL-33 in the 
presence and absence of the mTORC1 inhibitor rapamycin. Cell number was not affected by rapamycin following 
IL-33
0
50
100
150
 il
5
m
R
N
A
fo
ld
 in
du
ct
io
n
0
200
400
600
800
1000
 il
6 
m
R
N
A 
fo
ld
 in
du
ct
io
n
- + IL-33 - +
0
5
10
15
20
25
 il
9 
m
R
N
A 
fo
ld
 in
du
ct
io
n
IL-33 - +
0
500
1000
1500
 il
13
 m
R
N
A 
fo
ld
 in
du
ct
io
n
IL-33 - +
0
100
200
300
400
 G
M
-C
SF
 m
R
N
A 
fo
ld
 in
du
ct
io
n
IL-33 - +
p=0.006
p=0.01
p=0.053
p=0.0007 p=0.016
Figure 4. IL-33 stimulation of ILC2s increases cytokine mRNA levels. Cultured ILC2 were stimulated for 
6 h with IL-33 or left unstimulated. Total RNA was then isolated and the mRNA levels for the cytokines IL-5, 
IL-6, IL-9, IL-13 and GM-CSF were determined by qPCR as described in the methods. Results show mean of 3 
stimulations ±SD. Significance was calculated by the unpaired t-test with Welch’s correction.
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24 h of IL-33 stimulation (Fig. 8B). The production of IL-6 and IL-13 in response to IL-33 was however reduced 
by the presence of rapamycin, while the levels of IL-5 and GM-CSF were unaffected (Fig. 8C).
Discussion
We show here that inhibition of p38 blocks the production of multiple cytokines in response to IL-33. The study 
of cell signalling in ILC2s is restricted by the low number of these cells in vivo and the difficulty of obtained large 
numbers for study ex vivo. For the studies reported here, ILC2s were isolated from mesenteric fat, a tissue that 
contains a relatively high percentage of ILC2s, and maintained in culture using a combination of IL-2 and IL-7 
(Fig. 1). Knockout mice for IL-7Ra or the common γ chain cytokine receptor lack mature ILC2s61 indicating an 
important role for IL-7 in generating ILC2s in vivo. Both IL-2 and IL-7 have also been reported to help main-
tain ILC2 survival13,61 while culture in combination of IL-2 and IL-7 has been used to maintain ILC2s isolated 
from lung or Lin−ve ILC progenitors from bone marrow62,63. Mesenteric fat ILC2s maintained a Lin−ve/CD45+ve/
Sca1+ve/KLRG1+ve phenotype characteristic of ILC2s during culture. Similar to ILC2s directly isolated by FACS 
and stimulated immediately after isolation ex vivo, the cultured ILC2s produced IL-5, IL-6, IL-9 and IL-13 follow-
ing IL-33 stimulation. The kinetics of cytokine production was faster in the cultured ILC2s than the ex vivo ILC2s, 
possibly reflecting a priming effect of IL-2 and/or IL-7; both IL-2 and IL-7 have previously been reported to have 
a synergistic effect with IL-33 on cytokine production in ILC2s7,21,54.
We then looked at the role of MAPK signalling in regulating cytokine production in ILC2s (summarised 
in Fig. 9). Of the MAPK pathways tested, both the p38α/β and ERK1/2 pathways reduced the production of 
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Figure 5. Effect of MAPK pathway inhibition on cytokine production in ILC2 cells. (A) Cultured ILC2 
cells were plated at 5 × 103 cells per well and stimulated with IL-33 (100 ng/ml) in the presence or absence of 
either DMSO, the p38 inhibitor VX745 (1 µM) or the MEK1/2 inhibitor PD184352 (2 µM) for 24 h. Following 
stimulation the cells were stained with DAPI and counted on a BD FACSVerse. Graphs show total cell numbers 
and represent the mean and standard deviation of 3 biological replicates. (B–F) As in A, except plots show 
average of IL-5, IL-6, IL-9, IL-13 and GM-CSF concentration in the culture medium at 24 h and values were 
normalised per 1000 cells. Significance between samples was calculated using the one-way ANOVA test 
followed by the Tukey’s post hoc test. N.d indicates cytokine levels were below detectable limits in the assay.
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Figure 6. Effect of MK2/3 knockout of ILC2 numbers and IL-33 induced cytokine production. (A–D) 
Representative plots are showing percentage of Lineage−ve CD45+ve cells from all live single cells and percentage 
of KLRG1+ve Sca1+ve ILC2 cells within the Lineage−veCD45+ve population in lungs (A) mLN (B), mesentery (C) 
and eWAT (D) of WT and MK2/3 DKO mice. (E) Bar plots represent mean ± SD of absolute numbers of ILC2 
cells in the lungs, mLN, mesentery and eWAT for 4 mice per genotype. Symbols represent individual biological 
replicates. (F) Cultured ILC2 cells from WT and MK2/3 KO mice were stimulated with ±IL-33 (100 ng/ml) for 
24 hours. Following the stimulation cells were stained with DAPI (0.5 µg/mL) and absolute counts were obtained 
by BD FACSVerse. Supernatants were analysed by multiplex cytokine assay. Bar plots show mean concentrations 
of IL-5, IL-6, IL-9, IL-13 and GM-CSF ± SD and represent the average value of 4 biological replicates (each 
biological replicate was made by pulling cells from 4 mice). Values were normalised per 1000 cells. Significance 
was calculated by the unpaired t-test with Welch’s correction (E) or the non-parametric Mann-Whitney test 
where data did not follow normal distribution (F).
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multiple cytokines following IL-33 stimulation, with inhibition of p38 having the biggest effect. The finding that 
p38α and/or β is critical for IL-33 stimulated cytokine production is in agreement with previous studies on IL-33 
stimulated mast cells47,48, where p38 inhibition blocked IL-33 induced cytokine production. The use of VX745 
does not distinguish between p38α and β, however previous studies have indicated that blocking p38α is key to 
the anti-inflammatory effects of p38 inhibitors both in vivo and in isolated macrophages64,65. In mast cells, MK2 
and 3 were required downstream of p38α for the induction of IL-6, IL-13, GM-CSF, TNF, CCL3 and CCL447,48. 
In contrast to mast cells, the role of MK2 and 3 in ILC2s is more restricted as blocking MK2/3 reduced IL-6 and 
IL-13 production in response to IL-33 but had little effect on IL-5, IL-9 and GM-CSF induction. The relative 
importance of MK2/3 is therefore likely to be dependent on the cell type and cytokine. In agreement with this, 
previous studies on other innate immune cells have also shown that the ability of MK2/3 to regulate specific 
cytokines is cell type specific. For example, MK2 and 3 regulate TNF production in bone marrow derived mac-
rophages stimulated with TLR agonists but are not required for the production of IL-6 in bone marrow derived 
macrophages stimulated with TLR agonists47. In IL-33 stimulated bone marrow derived dendritic cells MK2/3 
regulate IL-13 production but not that of IL-666. The molecular mechanism of how MK2 and 3 regulate specific 
cytokines also appears to be cell type specific; for example while MK2 regulates TNF production in macrophages 
via the phosphorylation of TTP67 it regulates TNF is mast cells via a TTP independent mechanism47. In ILC2s 
one way in which MK2 and 3 may regulate IL-6 and IL-13 is via the mTORC1 pathway; p38 or MK2/3 inhibition 
blocked S6 phosphorylation in IL-33 stimulated ILC2s and the mTORC1 inhibitor rapamycin reduced IL-6 and 
IL-13 production to a similar level to that seen with MK2 inhibitors. mTORC1 regulation is complex and can be 
controlled by a number of inputs including PI3 kinase – Akt signalling, amino acid availability and by AMPK68. 
In macrophages the increase in PIP3 at the cell membrane seen following TLR stimulation is reduced by MK2/3 
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Figure 7. MK2/3 inhibition reduced IL-6 and IL-13 induction in ILC2s. (A) Total cell numbers of cultured 
ILC2 cells following 24 h stimulation with IL-33 in the presence or absence of Cmp2s (5 µM). (B) As in A, 
except plots show average of IL-5, IL-6, IL-13 and GM-CSF concentration in the culture medium. Values were 
normalised per 1000 cells. For A and B stimulations were done in triplicate and error bars show the mean value 
and standard deviation. (C,D) Human ILC2s were isolated from blood and where indicated treated with 1 µM 
VX745 (C), 5 µM Cmp2s (D) or DMSO. Cells were then cultured in the presence of IL-33 (10 ng/ml), IL-2 (5 ng/
ml), IL-25 (10 ng/ml) and TSLP (10 ng/ml) for 3 days. The levels of IL-6 and IL-13 present in the media were 
then determined as described in the methods. Graphs show comparisons between DMSO and VX745 (C) or 
DMSO and Cmp2s (D) for 6–7 individual donors. Statistical significance was determined using the one-way 
ANOVA test followed by the Tukey’s post hoc test (B) or paired t-test with Welch’s correction (C,D).
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inhibition resulting in reduced Akt activation57. It is possible that a similar mechanism may occur in ILC2 cells, 
with a reduction in Akt activation resulting in reduced activation of mTORC1.
Together these results indicate that the p38α/β is essential for the induction of IL5, IL-6, IL-9, IL-13 and 
GM-CSF in IL-33 stimulated ILC2s. In the case of IL-6 and IL-13, this requires the activation of the downstream 
kinases MK2 and, which in turn feed into that activation of mTORC1. Further studies will be required to deline-
ate the molecular mechanism by which p38 regulates IL-5, IL-9, and GM-CSF induction.
Methods
Animals. MK2/3 (Mapkapk2tm1mgl/Mapkapk3tm1mgl) knockout mice have been described previously69,70. Mice 
were maintained on a C57Bl/6J background and wild type mice for backcrossing obtained from Charles River 
Laboratories UK. Animals were maintained in specific pathogen-free conditions in line with EU and UK regula-
tions. Non breeding mice were housed in same-sex groups, in individually ventilated sterile cages and were given 
standard diet R&M1 or R&M3 (SDS, Special Diets Services). Animals were maintained in rooms with controlled 
12 h/12 h light/dark cycle, 21 °C temperature, and relative humidity of 45–65%. All the work was performed under 
a UK Home Office project license in accordance with UK and EU regulations and subject to local ethical review 
by the University of Dundee Ethical Review Committee.
Isolation of murine immune cells. Digestion of lungs and mesenteric fat was performed as previously 
described13. Briefly, lungs were cut into small segments and incubated in RPMI containing 50 µg/ml Liberase 
TM (Sigma Aldrich, Missouri, United States) and 10 µg/ml DNaseI (Roche, Basel, Switzerland) and incubated for 
45 min, at 37 °C. Tissue was passed through a 40 µm cell strainer (VWR, Pennsylvania, United States) and washed 
with 13 ml of 5% FBS in HBSS (Sigma Aldrich). Cell suspensions were centrifuged (450 g for 5 min at RT). Red 
blood cells were lysed by resuspending the pellet in 1 ml of RBC lysing Buffer (Sigma Aldrich). After 2 min at RT, 
cells were washed in 10 mL ice cold PBS, pelleted by centrifugation at 450 g for 5 min and resuspended in 10 ml 
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Figure 8. Crosstalk between MK2/3 and mTOR in ILC2 cells. (A) Cultured ILC2s were rested for 3 hours 
in ILC2 media lacking IL-2 and IL-7 and pre-incubated for a further 1 hour with 1 µM VX745, 5 µM Cmp2s 
or DMSO before stimulation with 100 ng/ml of IL-33 for 0 or 20 minutes. Phosphorylation of S6 ribosomal 
protein was measured by flow cytometry. Cells were gated based on FSC-A and SSC-A and the overlaid 
histograms show p-S6 (left panel). Bar plot show average of the median fluorescence intensity (MFI) of p-S6 
from two biological replicates (right panel). (B,C) Cultured ILC2 cells were pre-incubated with DMSO or 
rapamycin (20 nM) for 1 hour and then stimulated with IL-33 (100 ng/mL) for 24 hours. Control cells received 
DMSO but not IL-33. Following the stimulation cells were stained with DAPI (0.5 µg/mL) and analysed on BD 
FACSVerse to determine absolute numbers of live cells. (B) Plot represents ILC2 absolute numbers following the 
stimulation. (C) Concentration of IL-5, IL-6, IL-13 and GM-CSF in the culture media determined by multiplex 
cytokine assay. (B,C) Bar plots represent the mean ± SD of stimulations done in triplicate and statistical 
significance was determined using the one-way ANOVA test followed by the Tukey’s post hoc test.
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complete RPMI media (RPMI-1640 medium with 10% heat-inactivated FBS, 50 U/ml penicillin-streptomycin, 5 
mM L-glutamine, 10 mM HEPES buffer, 1 mM sodium pyruvate, 50 µM 2-mercaptoethanol) and filtered through 
a 40 µm cell strainer. White adipose tissue and mesenteric fat were dissected in DMEM containing 4% BSA (Sigma 
Aldrich). Tissues were cut into small fragments and incubated with 50 µg/ml Liberase TM (Sigma Aldrich) and 
10 µg/ml DNaseI (Roche) for 60 min at 37 °C. Cells were centrifuged (450 g for 5 min at RT) and RBC were lysed 
as described above.
Single cell suspensions from lymph nodes were obtained by gently mashing the lymph nodes through 40 µm 
nylon cell strainer in 5 ml of complete RPMI media. Cells suspensions were centrifuged at 450 g for 5 minutes at 
room temperature (RT) and red blood cells lysed as above.
Flow cytometry. For cell counting, cells were diluted 1:10 or 1:20 in PBS with 0.5 µg/ ml of DAPI (BioLegend, 
California, United States) and analysed on BD FACSVerse (BD, New Jersey, United States). Absolute numbers 
were calculated using FlowJo software (Tree Star, Inc., Oregon, United States). For analysis of cell surface mark-
ers, standard flow cytometry techniques were used. Briefly, cells were blocked with 50 µl rat anti-mouse CD16/
CD32 Fc block (BD, New Jersey, United States) (1:50 in FACS buffer (PBS + 1% BSA(Sigma)) and incubated for 
20 minutes at 4 °C. For detection of surface antigens, cells were stained with the appropriate fluorophore conju-
gated antibodies (listed in Table 2) for 20 minutes at 4 °C. Cells were then washed by adding 1 ml of FACS buffer 
and centrifuged at 450 g for 5 minutes at 4 °C. Pellets were resuspended in 400 µl of FACS buffer. For dead cell 
exclusion 0.5 µg/ ml of DAPI (Biolegend, California, United States) was added to the cell suspensions. For analysis 
of phospho-ERK1/2, phospho-p38 or phospho-S6 cells were stimulated with IL-33 for the indicated in the figures 
time point. Cells were then fixed by adding 4% PFA (Sigma) and incubated for 20 minutes at 4 °C. The cells were 
then washed twice by adding 1 ml of FACS buffer and centrifuged at 450 g for 5 minutes at 4 °C. Cells were perme-
balised by adding 1 ml of ice cold 90% methanol (VWR) while vortexing and then incubated overnight at −20 °C. 
Cells were washed by adding 1 ml of FACS, centrifuged at 450 g for 5 minutes at 4 °C and stained as described 
above. Samples were analysed using FACSCanto or BD LSRII Fortessa (BD) and results were further analysed by 
FlowJo software (Tree Star).
Culture of murine ILC2s. ILC2 cells were purified from mesenteric fat cell suspensions using magnetic 
sorting. 1 × 107 cells were incubated in 100 µl of CD16/CD32 Fc block (BD Biosciences) diluted 1:50 in MACS 
buffer (PBS containing 0.5% BSA and 20 mM EDTA (Thermo Fisher Scientific, Massachusetts, United States) for 
20 minutes at 4 °C. To deplete other immune cells, a cocktail of biotinylated anti-CD3, anti-CD11b, anti-CD11c, 
anti-Ly6C/Ly6G, anti-F4/80, anti-CD19, anti-B220, anti-NK1.1 and anti-TER119 antibodies (antibody dilutions 
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Figure 9. Model for MAPK regulated induction of cytokines in IL-33 stimulated ILC2s. Stimulation of ILC2s 
with IL-33 results in activation of the IL-33 receptor. This triggers formation of a Myddosome in which IRAK4 
and then IRAK1/2 are recruited to MyD88 resulting in the activation of Traf6 and then Tak1. Tak1 activates the 
IKK complex, which phosphorylates p105 resulting in the activation of Tpl2, which in turn activates the ERK1/2 
pathway. Tak1 also activates the p38 MAPK pathway leading to the activation of MK2 and 3. IL-33 also activates 
the mTOR pathway and MK2 and 3 promote activation of mTOR. The mechanism for this is unclear, but based 
on studies of Myd88 dependent signalling in macrophages could be due to MK2/3 promoting the generation of 
PIP3 at the plasma membrane. Both ERK1/2 and p38 promote the production of IL5, IL-6, IL-9, IL-13 and GM-
CSF while MK2/3 and mTOR selectively drive IL-6 and IL-13 production.
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are listed in Table 1) was added and cells were incubated for a further 20 minutes at 4 °C. Unbound antibodies 
were removed by washing in 10 ml of MACS buffer. Cells were incubated with streptavidin conjugated mag-
netic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) for 10 min at 4 °C according to manufacturer’s 
instruction. After incubation, cells were washed with 10 ml MACS buffer and pelleted by centrifugation (450 g 
for 5 minutes). The cell pellet was then resuspended in 1 ml of MACS buffer and passed through a LD depletion 
column that had been pre-wetted with MACS buffer (Miltenyi Biotec) and placed on a magnetic separator. The 
column was washed two times by adding 1 ml of MACS buffer. The flow through and washes were collected and 
cells were pelleted by centrifugation (450 g for 5 min). Cells were resuspended in 100 µl of biotinylated anti-CD45 
antibody diluted 1:200 in MACS buffer and incubated for 20 minutes at 4 °C. Cells were washed with MACS buffer 
and incubated with streptavidin microbeads for 10 minutes at 4 °C. After the incubation, the cells were washed in 
MACS buffer, resuspended in 1 ml of MACS buffer and passed through a pre-wetted MS column on a magnetic 
separator (Miltenyi Biotec). The column was washed twice with 1 ml of MACS buffer. The column was then 
removed from the magnetic separator and bound cells were eluted in 2 ml of MACS buffer. Cells were pelleted by 
centrifugation and then were cultured at a density of 0.5–1 × 105 in 200 µl of complete RPMI media supplemented 
with IL-2 (20 ng/ml) and IL-7 (10 ng/ml) for 5 days at 37 °C and 5% CO2. On day 3 half of the media was replaced 
with fresh media containing IL-2 (20 ng/ml) and IL-7 (10 ng/ml) (PeproTech, New Jersey, United States).
Flow cytometry sorting of murine ILC2s. Lineage negative cells were depleted using magnetic sort-
ing as described above from mesenteric cell suspensions. Cells were then stained with anti-Lineage, anti-CD45, 
anti-Sca1, anti-KLRG1 and anti-ST2 (Table 2) and DAPI (0.5 µg/mL) diluted in MACS buffer. ILC2 cells were 
defined as DAPI−veLineage−veCD45+veKLRG1+veSca1+veST2+ve and sorted on BD Influx™ cell sorter (BD).
Cell cycle analysis. 1 × 104 ILC2 cells were stimulated with IL-33 (100 ng/ml) for 48 hours. Following stim-
ulation cells were stained with Fixable Viability Dye eFluor™ 450 (eBioscience, California, United States) for 
10 minutes at 4 °C according to manufacturer instructions. Cells were fixed in ice cold 70% ethanol, washed twice 
with PBS. Samples were then incubated for 5 min with RNase A (100 μg/ml) (Thermo Fisher Scientific), stained 
with Propidium iodide (50 μg/ml) (Sigma-Aldrich) and analysed using BD LSRII Fortessa (BD). Results were 
further analysed by FlowJo software (Tree Star).
Stimulation of murine ILC2 cells. ILC2 cells were plated in 96 well plates at a density of 2500–5000 cells 
in 100 µl of complete RPMI media for stimulation. Where indicated, ILC2 cells were pre-incubated with the 
kinase inhibitors 1 µM VX745 (Selleckchem, #S1458), 2 µM PD184352 (Axon, #1386), 5 µM Cmp2s47 or 20 nM 
Rapamycin (Merck, #553210) for 1 hour before stimulation. Inhibitor concentrations were selected on the basis of 
the minimum amount required need to completely block the target kinase based on previous studies47,56,57,71–75. In 
line with results in other cells types, 2 µM PD184352 was able to completely block the phosphorylation of ERK1/2 
in ILC2s (Supplementary Fig. 3). PI184352 can also target the MKK5-ERK5 pathway but this required concentra-
tions higher than the 2 µM used in the experiments of ILC2s75. Inhibitors were dissolved in media containing 10% 
DMSO and diluted 1/100 into cell cultures, control cultures received the equivalent amount of DMSO. Cells were 
Target Fluorophore Clone Dilution Stock conc Source
CD11b FITC M1/70 1:200 0.5 mg/ml BioLegend
CD11c FITC N418 1:200 0.5 mg/ml BioLegend
CD19 FITC 6D5 1:200 0.5 mg/ml BioLegend
CD127 PE A7R34 1:200 0.2 mg/ml BioLegend
CD25 Alexaflour 700 PC61 1:200 0.5 mg/ml BioLegend
CD3ε FITC 17A2 1:200 0.5 mg/ml BioLegend
CD45 APC-eFluor 780 30-F11 1:200 0.2 mg/ml ThermoFisher
CD45 BV510 30-F11 1:200 0.2 mg/ml BioLegend
CD8 FITC 53–6.7 1:200 0.5 mg/ml BioLegend
c-Kit PE/Cy7 2B8 1:200 0.2 mg/ml BioLegend
F4/80 FITC BM4 1:200 0.2 mg/ml BioLegend
GATA3 PE 16E10A23 1:20 2.5 μg/ml BioLegend
KLRG1 APC 2F1 1:200 0.2 mg/ml BD Biosciences
Lineage PE mixed 1:50 BioLegend
NK1.1 FITC PK136 1:200 0.5 mg/ml BioLegend
Ly-6G/Ly-6C (Gr-1) FITC RB6-8C5 1:400 0.5 mg/ml BioLegend
Phospho ERK1/2 (Thr202/Tyr204) 
Antibody BV421 6B8B69 1:100 BioLegend
Phospho-p38 (Thr180/Tyr182) Alexaflour647 3D7 1:100 Cell Signalling
Phospho-S6 (Ser235/236) Alexaflour488 D57.2.2E 1:100 Cell Signalling
Sca1 APC/Cy7 D7 1:200 0.5 mg/ml BD Biosciences
ST2 PerCP-eFluor710 RMST2-2 1:200 0.2 mg/ml ThermoFisher
ST2 BV421 DIH9 1:200 0.2 mg/ml BioLegend
Table 1. Flow cytometry antibodies.
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stimulated with 100 ng/ml IL-33 for the times indicated in the figure legends. Control cells were left unstimulated. 
Following the stimulation, 50 µl from the culture media was carefully collected at the times indicated without 
disturbing the cells to measure cytokine production. At the end of the stimulation, cells were stained by adding 
150 µl of PBS with DAPI (0.5 µg/mL) in each well. Plates were analysed on a BD FACSVerse to determine absolute 
counts of live (DAPI negative) cells. For 5 day stimulations of ILC2, cells were plated in 100 µl of media. 50 µl of 
the culture media were collected on day 1 and day 3 and replaced with fresh 50 µl media with the corresponding 
stimuli and inhibitors. On day 5 the media was collected and cells were counted as described above.
Human ILC2 isolation and culture. ILC2 were isolated from peripheral blood and defined as Lin−ve (Lin: 
CD1a, CD3, CD4, CD14, CD16, CD19, CD34, CD56, CD94, CD123, CD336, CD303, FcεR1a, TCRαβ, TCRγδ)/
CD127+ve/CD161+ve/CRTH2+ve/c-Kitneg/pos, as previously described59. ILC2 cells from healthy donors were cul-
tured in X-vivo 15 medium (Lonza UK, BE02-060F.) containing 2% autologous human serum (Sigma-Aldrich 
Sweden AB, cat.Nr. H5667) at a concentration of 4 × 104 cells/ml in 96-well round bottom plates (4000 cells/well), 
preincubated with DMSO vehicle control, 1 µM VX745 and 5 µM Cmp2s and stimulated with IL-2 (5 ng/ml), 
IL-25, IL-33 and TSLP (10 ng/ml each) (R&D Systems, Minneapolis, MN, United States) for 3 days at 37 °C, 5% 
CO2. Supernatants were taken for mediator analysis. The gating strategy and purity of the human ILC2s is shown 
in Supplementary Fig. 7.
Cytokine assay. Supernatants from cell cultures were collected and stored in −80 prior to analysis. Cytokines 
in supernatants from mouse ILC2s were measured using a Luminex-based Bio-Plex assay (Bio-Rad Laboratories) 
using manufacturer’s instructions. Standards were reconstituted in the cell culture medium. Plates were read 
using a Luminex 100/200 machine and analysed using xPONENT® Software (Luminex, Texas, United States). 
For human ILC2s, cytokines in cell culture supernatants were measured using human U-plex kits (Meso Scale 
Discovery, Rockville MD, USA) according to manufacturer’s protocol.
qPCR. For RNA isolation cultured ILC2 cells were plated at concentration 1 × 104 cells per 100 μl in 96-well 
round bottom plates Total RNA was isolated using RNeasy Plus Micro Kit (Qiagen, Hilden, Germany) and reverse 
transcribed using iScript (BioRad, California, United States) according to the manufactures protocol. qPCR was 
carried out using Sybergreen based detection (Takara Biosciences, Kyoto, Japan). Primers sequences for IL-5 were 
forward: 5′-AGGCTTCCTGTCCCTACTCA-3′ and reverse: 5′-CCCCCACGGACAGTTTGATT-3′ and for IL-9 
were forward 5′-ATGTTGGTGACATACATCCTTGC-3′ and reverse 5′CGGCTTTTCTGCCTTTGCATCTC-3′. 
Other primer sequences were as described47. Fold induction relative to the unstimulated control cells was calcu-
lated76 as described using a combination of GAPDH and 18 s RNA levels for normalization.
Statistical analysis. Data were analysed and figures were made using GraphPad Prism 7.05 software 
(La Jolla, United States) and Adobe Illustrator and Indesign CC 2018 (Adobe, California, United States). The 
distribution was determined using the Shapiro-Wilk normality test. Pair-wise comparison of parametric and 
non-parametric data was done using the unpaired t-test with Welch’s correction or unpaired Mann-Whitney test, 
respectively. Multiple comparisons were performed using one-way ANOVA followed by Tukey’s post hoc test.
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